TABLE 1.
Baseline characteristics and type of cancer at time of diagnoses for patients in the dose escalation cohort (Part 1)
| Parameters | TV 1.5 mg/kg (N = 3) | TV 2.0 mg/kg (N = 3) |
|---|---|---|
| Age, years, median (range) | 38 (31–71) | 56 (42–70) |
| Male sex, n (%) | 3 (100) | 1 (33.3) |
| ECOG performance status at baseline, n (%) | ||
| 0 | 2 (66.7) | 1 (33.3) |
| 1 | 1 (33.3) | 2 (66.7) |
| Type of cancer at time of diagnosis, n (%) | ||
| Alveolar soft part sarcoma | 1 (33.3) | 0 |
| Cervical squamous cell carcinoma | 0 | 1 (33.3) |
| Esophagus squamous cell carcinoma | 1 (33.3) | 0 |
| Large cell neuroendocrine cancer | 1 (33.3) | 0 |
| Ovarian granulosa cell tumor | 0 | 1 (33.3) |
| Sigmoid colon adenocarcinoma | 0 | 1 (33.3) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; TV, tisotumab vedotin.